Santarus Reports Fourth Quarter and Full Year 2012 Financial Results

Company achieves record annual revenues of $218.0 million in 2012;

2012 net income of $18.6 million and $0.27 diluted EPS more than triple prior year period

Santarus, Inc. (SNTS), today reported financial and operating results for the quarter and year ended December 31, 2012.

Key financial results for the fourth quarter of 2012 include:

Phase 3 Trial of ZIOPHARM'S Palifosfamide in First-Line Metastatic Soft Tissue Sarcoma Reaches Target Number of Progression-Free Survival Events

Results Will be Announced Last Week of March

ZIOPHARM Oncology, Inc. (ZIOP) announced today that the Phase 3 (PICASSO 3) trial of palifosfamide (ZIO-201) in first-line metastatic soft tissue sarcoma has reached its target number of progression-free survival (PFS) events. PICASSO 3 is an international, randomized, double-blind, placebo-controlled trial whose primary endpoint is PFS. According to the protocol and statistical plan, reaching the target number of PFS events leads to completion of the blinded data collection process and then formal efficacy analysis by the IDMC (Independent Data Monitoring Committee). The Company will announce topline results from this trial during the last week of March 2013.

Published: 12 February 2013
Written by Editor
Nasdaq   Healthcare   Project Updates   Up on News   Interesting News  
Read more: ZIOPHARM Oncology Inc ( ZIOP )

AMRI Announces Fourth Quarter 2012 Adjusted EPS of $0.17

Provides Guidance for Full Year 2013 Adjusted EPS of $0.43 at Mid-Point

AMRI (AMRI) today reported financial and operating results for the fourth quarter and full year ended December 31, 2012.

Fourth Quarter:

Protalix BioTherapeutics Reviewing Partnering and Other Alternatives

Protalix BioTherapeutics, Inc. (PLX.TA) (PLX.TA), confirms, in response to inquiries received this morning and a report appearing in the Israeli press, that the company has engaged Citigroup to assist it in reviewing a broad array of product partnering, technology sharing and other strategic alternatives. There is no assurance that Protalix will undertake any such strategic alternative.

Protalix will not comment further on this initiative unless future events would make doing so appropriate.

Published: 05 February 2013
Written by Editor
Nasdaq   Healthcare   Up on News   Interesting News  
Read more: Protalix BioTherapeutics Inc ( PLX )

Merck Serono and Opexa Therapeutics Enter into Option and License Agreement for Development of Tcelna™ (imilecleucel-T) for Treatment of Multiple Sclerosis

Merck Serono granted option for exclusive license from Opexa to develop and commercialize Tcelna (imilecleucel-T), an investigational T-cell therapy for patients suffering from multiple sclerosis (MS)

Opexa Therapeutics, Inc. (OPXA) today announced the execution of an agreement with Merck Serono, a division of Merck, Darmstadt, Germany, for the development and commercialization of Tcelna™ (imilecleucel-T), a potential first-in-class personalized T-cell therapy for patients suffering from multiple sclerosis (MS). Tcelna (imilecleucel-T) is being developed by Opexa and currently is in a Phase IIb clinical trial in patients with Secondary Progressive MS (SPMS). Potential payments to Opexa from the option and license agreement could total $225 million based upon the successful development and commercialization of Tcelna for MS.

Published: 05 February 2013
Written by Editor
Nasdaq   Healthcare   Project Updates   Up on News   Interesting News  
Read more: Opexa Therapeutics Inc ( OPXA )
  1. Life Technologies Corporation ( LIFE )
  2. Hyperion Therapeutics Inc ( HPTX )
  3. Neuralstem Inc ( CUR )
  4. PharmAthene Inc ( PIP )
  5. BioTime Inc ( BTX )
Copyright © 2025 Stock Junction. All Rights Reserved.